There are a myriad of therapies widely used for migraine prevention. A few are both FDA-approved and possessed of a solid scientific evidence…
Read MoreEpitenzumab (Vyepti) was highlighted in this magazine as a “migraine treatment of the month” in the Fall 2022 issue…
Read MoreEver since injectable sumatriptan was approved for use in the US…
Read MoreExamined through the lens of the historical development of therapies for migraine, topiramate is a particularly interesting drug...
Read MoreEver since injectable sumatriptan was approved for use in the US…
Read MoreEach of the mABs is effective in a high percentage of patients...
Read MoreButterbur (scientific name Petasites hybridus) is a member of the sunflower family that grows in marshes and is largely found in southern Europe and parts of Asia…
Read MoreIn 1978 valproic acid (also known as sodium valproate or divalproex sodium) was approved by the FDA for seizure prevention…
Read MoreThe nervous system is a complex collection of interactive electronic circuits that conduct…
Although onabotulinumtoxinA (BotoxA) has been FDA-approved for the treatment of chronic migraine for well over 10 years…
Read MoreWithin the past two years 3 new oral medications intended for treatment of acute migraine headache…
Read MoreIndomethacin is hardly a newcomer to medical therapeutics. This nonsteroidal anti-inflammatory drug (NSAID) initially became available for general clinical use in 1963…
Read MoreFor this issue I decided to exercise some editorial prerogative and up the ante to feature two treatments of the month instead of the usual one.
Read MoreLearn how migraine and “dizziness” may be clinically and biologically linked.
Read MoreSince May 2018, within a period of just under two years, seven new medications for migraine treatment have received FDA approval and are available for routine clinical use. Our “Migraine Treatment of the Month” features the newest of the seven: rimegepant (Nurtec ODT; Biohaven Pharmaceuticals).
Read MoreDownload and complete this headache questionnaire prior to visiting your doctor if you want to get the most out of your visit.
Read MoreWith so many new therapies for migraine rapidly becoming available, it was difficult to pick one single therapy to highlight in this issue.
Read MoreEver since injectable sumatriptan was released (as Imitrex) for general clinical use in 1992, investigators have searched for a needle-less alternative for delivery of a triptan or triptan-like medication which would offer the same level of effectiveness, the same rapidity of effectiveness and the advantage of avoiding the oral route of administration in migraineurs experiencing nausea and vomiting with their headaches.
Read MoreMigraineur magazine is intended to both educate and entertain the many millions of people who suffer from migraine.
Blending information with enlivening entertainment, Migraineur is a unique resource for those who seek "to live well despite migraine". Written by medical professionals with extensive backgrounds in clinical work, research and education involving migraine, Migraineur's informational content goes far beyond what typically is offered via headache websites and other health magazines.
In doing so, however, the writers make a particular effort to ensure their articles offer an abundance of pragmatic advice relevant to the readers' needs, are enhanced by visually appealing graphics and are leavened with a healthy dose of humor. This is neither Readers Digest for migraine sufferers nor a dreary recitation of medical facts and statistics.
Instead, Migraineur is intended for a readership devoted to living healthy, productive and interesting lives. It is, put simply, a guide for living well and fully despite migraine.
For information regarding submissions advertising, letters-to-the-editor or other issues, contact the magazine's editorial office at: edoffice@migraineurmagazine.com
"Migraineur" has thousands of electronic subscribers throughout the U.S. and internationally. Become a subscriber, and you automatically will receive electronic notifications and the relevant links as soon as new issues are published or when blogs and special announcements are posted to the website to alert readers to new developments that occur between the publication of the quarterly issues. Subscribing to the magazine is simple and, better yet, free. Click below, provide your name, email address, and ZIP Code, and - voilà! - you are a subscriber.
Migraineur Wiki Page
View PDF
Spring 2024 Issue
Read online
Winter 2024 Issue
Read online
Fall 2023 Issue
Read online
Summer 2023 Issue
Read Online
Spring 2023 Issue
Read Online
Winter 2023 Issue
Read Online
Fall 2022 Issue
Read Online
Summer 2022 Issue
Read Online
Spring 2022 Issue
Read Online
Winter 2021-22 Issue
Read Online
Fall 2021 Issue
Read Online
Summer 2021 Issue
Read Online
Spring 2021 Issue
Read Online
Spring 2020 Issue
Read Online
Spring 2019 Issue
Read Online
Summer 2018 Issue
Read Online
About Contact Us Subscribe RSS Sitemap
Migraineur magazine is intended to both educate and entertain the many millions of people who suffer from migraine.
©2021 Celerity Press
🍀 Website design by Clover Collective
